Breakthrough Drug Extends Life Expectancy for Early-Stage Breast Cancer Patients, New Data Suggests
Jakarta, Indonesia – A new drug is showing remarkable promise in extending the lives of patients with early-stage breast cancer, potentially adding up to seven years to their life expectancy. Pharmaceutical company Lilly Oncology reports that late-stage clinical trial results for the drug, abemaciclib – sold under the brand name Verzenio – demonstrate a significant reduction in recurrence risk for certain types of breast cancer that have spread to lymph nodes.The findings, initially reported by ScienceAlert on August 31, 2025, are based on a seven-year follow-up study. While the data is currently awaiting peer review, Lilly Oncology has committed to presenting the full results at an upcoming medical conference and has submitted the research for publication.
“This data solidifies Verzenio’s position as a standard of care for high-risk patients with node-positive disease and underscores the urgent need to ensure all eligible patients have access to this treatment,” stated jacob Van Naarden, Director of Lilly Oncology.
Approved by the U.S. Food and Drug management (FDA) in 2017, Verzenio is an oral medication
